Bristol-Myers Squibb Company (BMY)

BMY (NYSE:Drugs) EQUITY
$55.67
pos +1.90
+3.53%
Today's Range: 54.62 - 56.13 | BMY Avg Daily Volume: 10,770,700
Last Update: 04/27/17 - 4:01 PM EDT
Volume: 15,305,155
YTD Performance: -7.99%
Open: $55.36
Previous Close: $53.77
52 Week Range: $46.01 - $77.12
Oustanding Shares: 1,647,500,265
Market Cap: 88,866,164,294
6-Month Chart
TheStreet Ratings Grade for BMY
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 7 7
Moderate Buy 1 1 1 1
Hold 6 6 5 6
Moderate Sell 0 0 0 0
Strong Sell 1 2 2 2
Mean Rec. 2.21 2.40 2.27 2.31
Latest Dividend: 0.39
Latest Dividend Yield: 2.89%
Dividend Ex-Date: 04/05/17
Price Earnings Ratio: 20.35
Price Earnings Comparisons:
BMY Sector Avg. S&P 500
20.35 20.40 30.60
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
14.84% -24.12% 6.48%
GROWTH 12 Mo 3 Yr CAGR
Revenue 17.30 0.20 0.06
Net Income 176.30 0.80 0.20
EPS 184.90 0.70 0.19
Earnings for BMY:
EBITDA 5.01B
Revenue 19.43B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $0.72 $0.70 $2.80 $3.03
Number of Analysts 7 6 11 9
High Estimate $0.74 $0.73 $2.85 $3.31
Low Estimate $0.70 $0.67 $2.74 $2.67
Prior Year $0.74 $0.69 $2.83 $2.80
Growth Rate (Year over Year) -2.32% 1.21% -1.22% 8.43%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
It doesn't look like Washington will be much help.
The market is off to a decent start as investors try to digest scores of first-quarter earnings reports. Bristol-Myers Squibb (BMY) is just one of many large-cap drug and biotech companies reporting today. BMY shares are up as earnings and revenue easily surpassed estimates, powered by Opdivo growth. AbbVie (ABBV) also is up nicely. Its oncology product Imbruvica posted an almost 45% rise in year-over-year sales while Humira continues to see sales growth in the mid-teens
S&P is already at resistance levels, where the advance appeared to stall.
Consider this BMY bullishly biased, near-the-money vertical call spread.
- Rev Shark, Yes, Market Lacks Fear, but There's No Emotion Either Several columns from me on the same theme today:   * I Fear the Absence of Fear of Loss  * More Wall Street Nonsense on Display  * Meshuganah Is Trump  * Thinking and Trading Opportunistically on the Short Side   Trade of the Week - Long a current fave - Allergan AGN!
It's pretty normal to have profit-taking after such a strong first quarter.
We know that we are in the era when index managers are ascendant.
Bonds rebounded from the recent weakness, with yields dropping (but only by a basis point). I am out of my (TBT) trade and maintaiing my (TLT) short investment. Wheat and corn higher. Old tech caught a bid -- (IBM) , (MSFT) and (INTC) . (FMC) , (AMD) , (VMC) , (MLM) and (PXD) . (AMZN) -liscious! Is (GILD) bottoming? (I am doing some research on this one now). (WMT) follow through from yesterday. (CMG) follow through from the last week (good call from Jim "El Capitan" Cramer). (CPB) catches a large, near one-million share buy from its majority shareholder -- on top of a $1.5 billion corporate repurchase program.  The Bad (JPM) a stickout to the downside in a mixed bank sector. (BMY) downside leader in Big Pharma. (GS) -- some profit taking after a +$10 rally from recent bottom. (I have no financial shorts, having covered all in Monday's early morning schmeissing, for profits). I am a short seller on strength, going forward.  The Ugly Soybeans -18. (XOM) down two beaners. (AN) -- Peak autos? (and OEMs, (GM) and (F) , have no "lift"). Optical weak --
"I would describe today's market action as "benign." And that applies to almost every asset class." -- Kass Diary
Most of the 10 best stocks of the bull market did it their way.

Columnist Conversations

join me today for a free webinar, we'll be talking about the markets, interest rates and the Fed.  after ...
we have a big winner here, we'll roll it up SOLD XLNX MAY 55 CALL AT 9.55 (in at 5.70) BOUGHT XLNX JUN 6...
View Chart »  View in New Window » XLY has met multiple upside targets, you may want to trail ...
WYN is ripping following this morning's earnings report. The lodging company is up over 8% and is in the numbe...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.